Emerging evidence suggests that intestine-specific FXR agonists may ameliorate hepatic steatosis through BA modulation, the suppression of hepatic gluconeogenesis, and the promotion of white adipose tissue thermogenesis, independent of hepatic FXR activation (31). Here, NR1H4 is linked to Hepatic steatosis.